Isarna Therapeutics Raises €5.5 Million
News Apr 25, 2014
Isarna Therapeutics GmbH has announced that it has raised Euro 5.5 million ($7.6M) in equity from its current investors including AT NewTec, Global Asset Funds, and MIG Fonds.
The company has also announced that Elizabeth Czerepak has joined Isarna’s management team as Chief Financial Officer and Chief Business Officer to lead the company’s new office location in New York City.
"Isarna is committed to its leadership in TGF-β and we see Elizabeth’s addition to our management team, as well as our expansion into the U.S., as key strategic steps toward building our presence in the global biotech industry,” said Dr. Philippe Calais, Chief Executive Officer at Isarna Therapeutics. “We are grateful for the continued support and confidence from our investors as we work to create Isarna’s future.”
“Isarna’s goal of unlocking the power of TGF-β for cancer immunotherapy and as an innovative approach for treating ocular diseases and fibrosis is tremendously exciting and I am excited to join this impressive team and make an impact toward achieving success for the company,” added Ms. Czerepak.
Elizabeth Adkins Czerepak, MBA, brings to Isarna twenty-one years of pharmaceutical and biotechnology leadership experience and nine years as a venture capital investor at JP Morgan and Bear Stearns.
Ms. Czerepak has served in executive-level finance, licensing and corporate development positions, most recently as Chief Financial Officer and Principal Accounting Officer at Cancer Genetics, Inc. (CGIX), that she took public on NASDAQ and for which she raised three rounds of public financing totaling $69M.
Prior to CGI, Elizabeth worked at BASF Pharma (Knoll), Hoffmann-La Roche and Merck & Co.
Single Blood Test 'CancerSEEK' Screens for Eight Cancer TypesNews
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.READ MORE
Radical New Approach to Vaccine Development Could Help Reduce Illness From FluNews
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help lower that figure for future flu seasons.READ MORE
Small Compound Able to Stave Tumor and Stop its GrowthNews
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital nutrient glutamine.READ MORE